Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Common Equity (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Common Equity for 7 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 68.82% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 68.82% year-over-year, with the annual reading at $1.2 billion for FY2025, 68.82% up from the prior year.
  • Common Equity for Q4 2025 was $1.2 billion at Beam Therapeutics, up from $966.0 million in the prior quarter.
  • The five-year high for Common Equity was $1.2 billion in Q4 2025, with the low at $422.4 million in Q1 2021.
  • Average Common Equity over 5 years is $836.4 million, with a median of $819.2 million recorded in 2021.
  • The sharpest move saw Common Equity surged 326.76% in 2021, then fell 25.25% in 2024.
  • Over 5 years, Common Equity stood at $826.7 million in 2021, then decreased by 11.28% to $733.5 million in 2022, then soared by 33.79% to $981.3 million in 2023, then dropped by 25.25% to $733.5 million in 2024, then skyrocketed by 68.82% to $1.2 billion in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $1.2 billion, $966.0 million, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.